Amarin may indeed see that windfall

If you shut down your computer early Friday, you may have missed the news: Amarin got the FDA go-ahead for expanded use of its fish oil-derived heart drug. The drug maker may now proclaim that Vascepa prevents heart attacks, strokes, and other such severe cardiovascular events — setting the company up for quite the potential blockbuster. The market for such a drug, after all, could be in the billions — in the US alone.

That said, the FDA has placed some limitations on Vascepa, STAT’s Matthew Herper writes, saying it can only be used in patients who already have some form of diabetes or cardiovascular disease.